Table 4.
Clinical characteristics of reported cases of synchronous intestinal carcinoma and lymphoma in the literature.
| References | Age (year) | Gender | Lymphoma | Hepatocellular carcinoma | Chemotherapy regimens | OS (months) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | Staging | Treatment | Diagnosis | Staging | Treatment | |||||
| Kidd et al. (9) | 67 | Female | HL | IIA | Chemo | Rectal moderately differentiated adenocarcinoma | pT2 N0 M0, Dukes' A | Ope | ABVD | >27 |
| 74 | Female | DLBCL | Not described | – | Cecal adenocarcinoma | pT3 N0 M0, Dukes' B | – | – | <1 | |
| 65 | Male | HL | III | Chemo | Rectal moderately differentiated adenocarcinoma | ypT3 yN2 M0, Dukes' C1 | Ope, Chemo |
ABVD, capecitabine |
>12 | |
| 62 | Female | HL | I | watch and wait | Sigmoid colon moderately differentiated adenocarcinoma | pT3 N0 M0, Dukes' B | Ope | – | >29 | |
| 33 | Male | FL (grade 1) | I | - | Rectosigmoid moderately differentiated adenocarcinoma | pT3 N0 M0, Dukes' B | Ope | – | >120 | |
| Cui et al. (10) | 53 | Female | DLBCL | Not described | Chemo | Sigmoid colon adenocarcinoma | pT3N0M0, stage II | Ope | R-CHOP | 7 |
| Yang et al. (11) | 73 | Male | DLBCL | II | Chemo | Sigmoid colon well-differentiated adenocarcinoma | pT3N0M0, stage IIA | Ope | R-CHOP | >4 |
| Present case | 78 | Male | DLBCL | IV | Chemo | Duodenum papilla adenocarcinoma | – | Chemo | R-miniCHOP, S-1 | 16 |
| 65 | Female | DLBCL | III | Chemo | Sigmoid colon adenocarcinoma | pT2 N0 M0, I | Chemo, Ope | R-CHOP, S-1 | >33 | |
ABVD, Adriamycin, bleomycin, vincristine, dakabazine; DLBCL, diffuse large B-cell lymphoma; Chemo, chemotherapy; Ope, operation; R-CHOP, rituximab, cyclophosphamide, Adriamycin, vincristine, and prednisone; OS, overall survival; FL, follicular lymphoma; HL, Hodgkin lymphoma.